A Phase 2 Study of Pemetrexed versus Pemetrexed + Erlotinib in Second-Line Treatment in Patients with Nonsquamous NSCLC

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-005118-11

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Evaluate progression free survival between Pemetrexed 500 mg/m² every 3 weeks + Erlotinib 150 mg daily and Pemetrexed 500 mg/m² every 3 weeks when given as second line therapy for the treatment of locally advanced or metastatic nonsquamous Non Small Cell Lung Cancer


Critère d'inclusion

  • Patients who have histologically or cytologically documented diagnosis of nonsquamous NSCLC (Stage IIIA, IIIB or IV at entry), with progressive disease after treatment with 1 prior chemotherapy regimen for locally advanced or metastatic disease, who are considered for second line therapy and who meet the other disease criteria